FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 10/2023 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 10/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of October 2023 we identify the following current VC trends in Europe:

• In 2023, overall Life Sciences funding has reached EUR 7,324m
• Biotech received 42% of the total investment volume (-3% compared to the previous month)
• Oncology dominates as the top indication in Biotech
• AgomAb Therapeutics (Belgium) has the highest transaction volume of EUR 94m in October, followed by MinervaX (Denmark) EUR 54m and AstronauTx (United Kingdom) EUR 54m
• The EIC Fund (vehicle of the European Innovation Council, Belgium) dominates the Top 5 Investors (by deal volume), followed by Revival Healthcare Capital (United States) and Gilde Healthcare Partners (Netherlands)
• Top 5 Deals exceed EUR 130m each, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)

To access the full report, please click here.